Albendazole observational studies

The substantial differences (from single dose ABZ) observed in the plasma and tissue residue profiles in this study, tend to indicate that the quantitative metabolic profile may be altered in the case of the sustained-release of albendazole. If the established Rm = 0.2 factor is applied to the marker metabolite concentration of 651 ppb observed at 0-day withdrawal in this study, a total residue of 3255 ppb (651x5) would be indicated. However, considering the facts that... 

The efficacy of ivermectin for human onchocerciasis was established in the 1980s and is summarized in this chapter briefly. Clinical study of ivermectin in human strongyloidiasis has not yet been completed. Here we describe the efficacy of ivermectin for human strongyloidiasis as observed in our institution during the past decade. Furthermore, we would like to describe the combination therapy with ivermectin and albendazole for bancroftian filariasis and also the efficacy of ivermectin in the treatment of human scabies. 

Albendazole is a broad-spectrum antihelminthic drug used to treat the tropical parasitic disease, human neurocysticercosis. Albendazole contains a sulfur group that is subject to oxidation to an active sulfoxide metabolite. The S-oxide metabolite forms a center of asymmetry at the sulfur atom, thus conferring chirality to the molecule. Albendazole sulfoxide steady-state pharmacokinetics have been studied in 18 patients with confirmed active neurocysticercosis after repeated dose administration of 5mg/kg thrice daily for 8 days [44]. A high degree of stereoselectivity was observed in the plasma concentrations of the sulfoxide metabolite, with Cmax and AUCss (-I-) (—) ratios of 5.5 and 9.2, respectively. It is not known if there is stereoselectivity in the antihelminthic activity of the (-1-)- and (—)-sulfoxide metabolites of albendazole. 

---